Deals
AbbVie Wins U.S. Antitrust Nod for Botox Maker Allergan
- FTC votes 3-2 to clear blockbuster deal with conditions
- Republican, Democratic commissioners clash over decision
This article is for subscribers only.
AbbVie Inc. won U.S. antitrust approval for its acquisition of Botox maker Allergan Plc, clearing the last hurdle from competition regulators to the $63 billion deal.
The Federal Trade Commission said late Tuesday that it signed off on the takeover after the companies agreed to resolve competition concerns by selling two products to Nestle SA and transferring to AstraZeneca Plc the rights to a treatment for Crohn’s disease that’s in development.